Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters








Language
Year range
1.
China Pharmacy ; (12): 1115-1118, 2023.
Article in Chinese | WPRIM | ID: wpr-972957

ABSTRACT

OBJECTIVE To compare efficacy and safety of continuous pump versus intermittent infusion of amphotericin B in the treatment of invasive fungal infection, and to provide evidence-based reference for clinical treatment. METHODS Retrieved from PubMed, the Cochrane Library, Web of Science, Embase, Wanfang, CNKI, CBM and VIP database, randomized controlled trial (RCT) and cohort study about 24 h continuous pump (trial group) versus intermittent infusion (control group) of amphotericin B were collected from the inception to Jan. 2023. After literature screening and data extraction, the quality of RCT was evaluated with modified Jadad scale, and the quality of cohort study was evaluated with Newcastle-Ottawa scale. Meta-analysis and sensitivity analysis were performed by using RevMan 5.4 software. RESULTS A total of 7 literature were included, involving 1 RCT and 6 cohort studies with a total of 767 patients. The results of meta-analysis showed that the clinical effective rate [RR=1.44, 95%CI (1.13,1.83), P=0.003] of trial group was significantly higher than that of control group, and all-cause mortality rate [RR=0.37, 95%CI(0.19,0.72),P=0.003] and the incidence rate of infusion reaction [RR=0.28,95%CI(0.18,0.43), P<0.000 01] were significantly lower than control group; there was no statistical significance in the incidence rate of renal impairment between 2 groups [RR=0.71,95%CI(0.45,1.11),P=0.13] . The sensitivity analysis results showed that the results obtained in this study were robust. CONCLUSIONS The efficacy and safety of 24 h continuous pump of amphotericin B are better than those of intermittent infusion in the treatment of invasive fungal infection.

2.
China Pharmacy ; (12): 497-502, 2022.
Article in Chinese | WPRIM | ID: wpr-920469

ABSTRACT

OBJECTIVE To systematically evaluate the adverse effects of drug-resistant tuberculosis (DR-TB) drugs on pregnant women and fetuses ,so as to provide evidence-based reference for clinical medication. METHODS PubMed,Cochrane Library,Embase,CBM,CNKI,Wanfang database and VIP were searched by computer to collect randomized controlled trials (RCTs),cohort studies ,case-control studies ,case series and case reports about pregnant women exposed to DR-TB drugs. The retrieval time limit was from the establishment of each database to August 20,2021. After selecting the literature and extracting the data,the bias risk assessment tool recommended by 6.2 version of Cochrane system evaluator manual was used to evaluate the quality of the included RCTs ;Newcastle-Ottawa scale was used to evaluate the quality of the included cohort studies and case-control studies ;IHE scale issued by the Canadian Institute of Health Economics (IHE)was used to evaluate the quality of the included case series and case reports. RevMan 5.1 software was used for Meta-analysis of non-comparative binary data. RESULTS A total of 13 literature were included ,including 7 case series and 6 case reports ,involving 203 patients and 204 newborns;among them,there were 6 literature about non-comparative binary data. The results of meta-analysis showed that after exposure to DR-TB drugs,no newborn had birth defects ;the mortality of pregnant women was 0.09[95%CI(0.06,0.15),P<0.000 01];the neonatal mortality was 0.02[95%CI(0,0.06),P<0.000 01];the incidence of preterm birth was 0.14[95%CI(0.03,0.43),P=0.02];the incidence of infants with low birth weight was 0.17[95%CI(0.04,0.51),P=0.06];the incidence of growth retardation was 0.15[95%CI(0.09,0.22),P<0.000 01];the incidence of stillbirth was 0.05[95%CI(0.02,0.09),P<0.000 01];the incidence of abortion was 0.08[95%CI(0.05,0.14),P<0.000 01]. CONCLUSIONS Pregnant women exposed to DR-TB drugs can cause pregnant women ’s death and abortion ,neonatal death ,premature birth ,infants with low birth weight ,growth retardation and stillbirth,but there is no neonatal birth defect ;these adverse outcomes may be related to the history of DR-TB.

3.
China Pharmacy ; (12): 2400-2405, 2021.
Article in Chinese | WPRIM | ID: wpr-886924

ABSTRACT

OBJECTIVE:To evaluate the efficacy and safety of atomization inhalation of polymyxin combined in the adjunctive treatment for ventilator-associated pneumonia ,and to provide evidence-based reference for clinical treatment. METHODS : Retrieved from Cochrane Library ,Embase,PubMed,Web of Science ,CNKI,CBM,VIP and Wanfang database (from their inception to March 2021),randomized controlled trials (RCTs)about efficacy and safety of atomization inhalation of polymyxin combined with conventional treatment (trial group ) versus conventional treatment (control group ) for ventilator- associated pneumonia were collected. After data extraction and quality evaluation of included literatures met inclusion and exclusion criteria , Meta-analysis was performed by using Rev Man 5.4 software. RESULTS :A total of 13 clinical studies were included ,involving 2 RCTs and 11 cohort studies with a total of 1 066 patients. The results of Meta-analysis showed that clinical response rate [OR = 1.53,95%CI(1.17,2.00),P=0.002],microbial clearance rate [OR =1.46,95%CI(1.11,1.91),P=0.007] of trial group were significantly higher than those of control group ,with statistical significance. There was no statistical significance in the mortality rate [OR =0.88,95%CI(0.68,1.14),P=0.32] and the incidence of renal impairment [OR =1.04,95%CI(0.72,1.49),P=0.85] between 2 groups. CONCLUSIONS :Based on current evidence ,atomization inhalation of polymyxin combined with conventional treatment can significantly improve clinical response rate and microbial clearance rate of patients with ventilator- associated pneumonia. However , more strictly-designed , long-term follow-up and large-scale RCTs are needed.

SELECTION OF CITATIONS
SEARCH DETAIL